Bachem Holding AG

Equities

BANB

CH1176493729

Biotechnology & Medical Research

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
86.4 CHF +2.19% Intraday chart for Bachem Holding AG +2.80% +32.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Switzerland's Bachem Reports Improved FY23 Net Income, Sales MT
Transcript : Bachem Holding AG, 2023 Earnings Call, Mar 07, 2024
Bachem Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Bachem Holding AG - Special Call
Sandoz Spin-off Prompts Swiss Extraordinary Index Changes in October MT
Bachem CEO Assumes Operations Chief Role Amid Executive Committee Shakeup MT
Transcript : Bachem Holding AG, H1 2023 Earnings Call, Jul 27, 2023
Bachem Posts Lower H1 Net Income; Sales Up MT
Bachem Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Charts in perspective Our Logo
Is the Fed's message bizarre? Our Logo
Certain Shares of Bachem Holding AG are subject to a Lock-Up Agreement Ending on 8-JUN-2023. CI
Global markets live: EssilorLuxottica, AT&T, Tesla, Credit Suisse, Sony... Our Logo
Bank Vontobel Lifts Price Target on Bachem, Maintains Hold Recommendation MT
Bachem Raises CHF108 Million to Expand Capacity at Swiss Sites MT
Bachem Plans Capital Raising to Expand Capacity at Swiss Sites MT
Bachem Posts Lower FY22 Attributable Net Income MT
Bachem Holding AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Bachem Wins CHF500 Million Order for Peptides Supply Until 2031 MT
Credit Suisse Lifts Price Target Bachem, Maintains Outperform Recommendation MT
Swiss Biotech Bachem Secures CHF1 Billion Contract to Deliver Peptides for Five Years MT
Octavian Lifts Price Target on Bachem, Maintains Buy Recommendation MT
European shares retreat amid interest rate jitters, recession fears RE
Biotechnology Group Bachem To Buy New Site In Switzerland MT
Global markets live: Apple, United Health, Ford, PepsiCo, Peloton... Our Logo
Chart Bachem Holding AG
More charts
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
6
Last Close Price
84.55 CHF
Average target price
70.8 CHF
Spread / Average Target
-16.26%
Consensus
  1. Stock
  2. Equities
  3. Stock Bachem Holding AG - Swiss Exchange
  4. News Bachem Holding AG
  5. Bachem : On Track To Reach Targets As H1 Profit, Sales Soar